The Motley Fool
13 Jul 2026, 00:20 UTC · 2h ago
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
13 Jul 2026, 00:20 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
ANI Pharmaceuticals raised its full-year revenue guidance to between $1.08 billion and $1.14 billion and adjusted earnings to $9.19–$9.69 per share. — Upwardly revised guidance and earnings estimates are strong positive signals for valuation and stock price.
+0.60The board of ANI Pharmaceuticals authorized a $100 million share buyback in May. — Buybacks reduce share count and signal management's confidence in the company's intrinsic value.
+0.40ANI Pharmaceuticals' first-quarter revenue grew 20.5% to $237.5 million, largely driven by a 42.1% increase in Cortrophin Gel sales. — Strong top-line growth and high demand for a key product indicate healthy operational momentum.
+0.30Continue reading
6 related stories
Search tags
CFO Stephen P. Carey sold 3,313 shares of common stock on July 2, 2026, as part of a pre-planned trade from March. — While insider selling can be a red flag, this was a small fraction (2%) of his holdings and executed under a pre-set plan, making it low-signal.
-0.10Which stocks this story touches
The company reported strong revenue growth, raised full-year guidance, and authorized a $100 million buyback.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
5h ago
